Statistical analyses were performed with SPSS version 13.0 software (SPSS, Inc., Chicago, IL)
Insomnia is an increasingly common medical condition reported by up to 50% of older adults (greater than or equal to 55 years old)
In brief, up to 1 million cells were resuspended in a total of 180 L freshly prepared FACS Buffer (PBS, 1% FSC, 2 mM EDTA)
A 2019 study in the Journal of Peptide Science demonstrated that lyophilised GLP-1 agonists stored at 4C retained only 78% potency after six months, compared to 96% retention at 20C
FDA-approved pharmacotherapy alternatives include several options with established safety profiles: Semaglutide (Wegovy): A GLP-1 receptor agonist producing 12-15% weight loss, with cardiovascular benefits demonstrated in the SELECT trial and FDA-approved indication for reducing cardiovascular risk Liraglutide (Saxenda): A GLP-1 receptor agonist producing 5-8% weight loss [4] Phentermine-topiramate (Qsymia): FDA-approved combination producing 7-10% weight loss with established safety data Naltrexone-bupropion (Contrave): Combination targeting reward pathways and appetite, producing 5-9% weight loss [4] Orlistat (Xenical, Alli): Lipase inhibitor producing 3-5% weight loss with gastrointestinal side effects [4] Setmelanotide (Imcivree): For rare genetic obesity disorders (POMC, PCSK1, LEPR deficiency) [4] Metabolic and bariatric surgery should be considered for patients with BMI 40 kg/m or 35 kg/m with obesity-related comorbidities who have not achieved adequate weight loss with nonsurgical interventions
it can significantly enhance body shape and proportion by reducing stubborn fat pockets resistant to diet and exercise
